The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
CSL Seqirus opened in 2015 and is the second largest influenza company in the world.
We support collaborative innovation through the endowment of awards and grants to researchers around the world.
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Dev…
CSL statement in response to media reports on case against Joseph Chiao
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange …
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatm…
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbour…
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a n…
Popular search terms:
Americas
Asia Pacific
MIddle East
Europe
Middle East
